Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;13(1):22-26.
doi: 10.1159/000486330. Epub 2018 Jan 31.

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

Florian Schütz  1 , Frederik Marmé  2 , Christoph Domschke  1 , Christof Sohn  3 , Alexandra von Au  1
Affiliations
Review

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

Florian Schütz et al. Breast Care (Basel). 2018 Mar.

Abstract

Immunotherapies are set to become part of the therapeutic repertoire for breast cancer in the near future. Active vaccination is a promising strategy, especially in tumors that have a specific tumor-associated antigen. Although cellular immunotherapies have not yet shown efficacy, new technologies are on the way to improve this approach. Given the recent Food and Drug Administration approval of chimeric antigen receptor (CAR) T cells for leukemia, it is only a question of time before solid tumors will follow. However, not all breast cancer patients will respond to cellular or other immunotherapy. Hence, we must define subpopulations of breast cancer patients who benefit from this new approach.

Keywords: Dendritic cells; Immunotherapy; T cells; Vaccines.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. - PubMed
    1. Moasser MM. Two dimensions in targeting HER2. J Clin Oncol. 2014;32:2074–2077. - PMC - PubMed
    1. Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017;280:249–279. - PubMed
    1. Hanna MG, Jr, Peters LC. Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery. Cancer. 1978;42:2613–2625. - PubMed
    1. Berger M, Kreutz FT, Horst JL, Baldi AC, Koff WJ. Phase I study with an autologous tumor cell vaccine for locally advanced or metastatic prostate cancer. J Pharm Pharm Sci. 2007;10:144–152. - PubMed

LinkOut - more resources